Sign In
Buy CGEN
$2.19
-0.0700 (-3.10%)
At Close: Jun 03, 2026
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U.S. Food and Drug Administration has cleared the inve
Compugen Doses First Patient In COM701 Phase 1 Monotherapy Expansion Cohort
11:11am, Wednesday, 27'th May 2020Compugen Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort
11:00am, Wednesday, 27'th May 2020
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in the monotherapy expans
2 Top Biotech Picks for May
11:02am, Wednesday, 20'th May 2020
The art of biotech investing requires a great deal of scientific knowledge, awareness of financials, and patience in waiting for clinical trials to come to fruition. Today, let's examine two of the b
Is the Options Market Predicting a Spike in Compugen (CGEN) Stock?
12:46pm, Monday, 18'th May 2020
Investors need to pay close attention to Compugen (CGEN) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Compugen (CGEN) Stock?
12:00am, Monday, 18'th May 2020How Compugen (CGEN) Stock Stands Out in a Strong Industry
01:48pm, Wednesday, 13'th May 2020
Compugen (CGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
